6.
Mohammed N, Antonopoulos A, Dell A, Haslam S, Dimitroff C
. The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma. Adv Cancer Res. 2023; 157:157-193.
PMC: 9895887.
DOI: 10.1016/bs.acr.2022.06.001.
View
7.
Yu L
. Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol. 2010; 2(4):177-80.
PMC: 2999182.
DOI: 10.4251/wjgo.v2.i4.177.
View
8.
Nangia-Makker P, Hogan V, Raz A
. Galectin-3 and cancer stemness. Glycobiology. 2018; 28(4):172-181.
PMC: 6279147.
DOI: 10.1093/glycob/cwy001.
View
9.
Lobos-Gonzalez L, Aguilar L, Diaz J, Diaz N, Urra H, Torres V
. E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment Cell Melanoma Res. 2013; 26(4):555-70.
PMC: 3695072.
DOI: 10.1111/pcmr.12085.
View
10.
Califice S, Castronovo V, Bracke M, van den Brule F
. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene. 2004; 23(45):7527-36.
DOI: 10.1038/sj.onc.1207997.
View
11.
Wong C, Dye D, Coombe D
. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol. 2012; 2012:340296.
PMC: 3261479.
DOI: 10.1155/2012/340296.
View
12.
Jin H, Wang C, Jin G, Ruan H, Gu D, Wei L
. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1. Gastroenterology. 2017; 153(3):799-811.e33.
DOI: 10.1053/j.gastro.2017.05.045.
View
13.
Shoshan E, Braeuer R, Kamiya T, Mobley A, Huang L, Vasquez M
. NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis. Cancer Res. 2016; 76(11):3145-55.
PMC: 4891299.
DOI: 10.1158/0008-5472.CAN-15-2511.
View
14.
Girouard S, Laga A, Mihm M, Scolyer R, Thompson J, Zhan Q
. SOX2 contributes to melanoma cell invasion. Lab Invest. 2011; 92(3):362-70.
PMC: 3887365.
DOI: 10.1038/labinvest.2011.188.
View
15.
Lopes J, Rodrigues C, Gaspar M, Reis C
. Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers (Basel). 2022; 14(19).
PMC: 9562203.
DOI: 10.3390/cancers14194652.
View
16.
Mourad-Zeidan A, Melnikova V, Wang H, Raz A, Bar-Eli M
. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol. 2008; 173(6):1839-52.
PMC: 2626394.
DOI: 10.2353/ajpath.2008.080380.
View
17.
Shannan B, Perego M, Somasundaram R, Herlyn M
. Heterogeneity in Melanoma. Cancer Treat Res. 2015; 167:1-15.
DOI: 10.1007/978-3-319-22539-5_1.
View
18.
van den Brule F, Waltregny D, Liu F, Castronovo V
. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer. 2000; 89(4):361-7.
DOI: 10.1002/1097-0215(20000720)89:4<361::aid-ijc8>3.0.co;2-u.
View
19.
Takenaka Y, Fukumori T, Raz A
. Galectin-3 and metastasis. Glycoconj J. 2004; 19(7-9):543-9.
DOI: 10.1023/B:GLYC.0000014084.01324.15.
View
20.
Abdou A, Hammam M, El Farargy S, Farag A, El Shafey E, Farouk S
. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma. Am J Dermatopathol. 2010; 32(8):809-14.
DOI: 10.1097/DAD.0b013e3181e02f29.
View